All In Biotech

Drug Trial Radar · NCT07950332

A Phase II Clinical Study of HRS-7172 as Monotherapy or in Combination With Anti-Tumor Therapy in Participants With Advanced Lung Cancer to Evaluate Safety, Tolerability, and Efficacy

A Phase II Clinical Study of HRS-7172 as Monotherapy or in Combination With Anti-Tumor Agents in Participants With Advanced Non-Small Cell Lung Cancer to Evaluate Safety, Tolerability, and Efficacy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 1, 2028

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-7172 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-7172 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.

Conditions

  • Lung Cancer

Interventions

  • HRS-7172 tabletDrug

    HRS-7172 tablet fixed dose

  • HRS-7172; SHR-4610 ; chemotherapyDrug

    HRS-7172 fixed dose+ /SHR-4610 fixed dose± chemotherapy fixed dose

  • HRS-7172 ; SHR-9839(sc) ; SHR-4610Drug

    HRS-7172 fixed dose+SHR-9839(sc) fixed dose b/SHR-4610 fixed dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v6.0)Time frame: 2 month
  2. Determine dose recommendation (RP2D)Time frame: 6month
  3. Objective response rate (ORR)Time frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Zhejiang Tumor Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.